Endometriosis (NHP-07)

Endometriosis


Endometriosis (NHP-07)

NHP-07 – First pharmaceutical/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk® as a companion diagnostic/prognostic is the only treatment protocol that can prevent development of endometriosis and, in women experiencing advanced stages of endometriosis NHP-07, stop the progression of the disease while suppressing the debilitating symptoms.

 

  • Expected launch 2018
  • Approximately 7.5 million women suffer from endometriosis in the United States with only 2.5 million women currently diagnosed
  • 5 million women are estimated to suffer from endometriosis in the major international markets with 70 million women suffering globally
  • Greater than $1Billion annual US market
  • Tremendous need for new more effective/lower side-effect therapeutics to meet this unmet demand
  • Suppresses the symptoms of endometriosis in women diagnosed with endometriosis
  • Prevents the development of the disease
  • Believed to be superior to all competitive pharmaceuticals currently on the market
  • Combination of two or more existing FDA-approved compounds, whose safety has already been established over decades
  • Coupled with EndoRisk® as a companion diagnostic NHP-07 can be given prior to development of endometriosis or becoming symptomatic to prevent the disease altogether
  • Patent pending for combination of progesterone and NSAIDs (Non Steroidal Anti-Inflammatory Drugs)
  • Patent pending to replace traditional NSAIDs with cannabinoids to reduce the long-term side effects of NSAIDs